NR1I3 and cancer: Chen et al. [6] considered one promising option involving the use of CAR (Constitutive Androstane Receptor, NR1I3) and PXR (pregnane-X receptor, NR1I2) ligands in combination with chemotherapeutics that activate PXR and CAR to overcome, or at least attenuate multi-drug resistance (MDR) in cancer cells.